Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ribavirin monophosphate is the phosphorylated metabolite of the antiviral drug ribavirin. It is a synthetic guanosine nucleoside analog that acts as a competitive inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH), mimicking inosine 5′-monophosphate. This inhibition disrupts de novo synthesis of guanine nucleotides and decreases intracellular GTP pools, leading to reduced viral protein synthesis and limited replication of viral genomes[1][4]. Ribavirin itself is used as an antiviral agent against several RNA and DNA viruses—primarily hepatitis C virus (in combination with interferon) and certain viral hemorrhagic fevers[1][2][4]. Ribavirin monophosphate is not administered directly as a drug but represents an active intermediate in the metabolic pathway of orally or parenterally administered ribavirin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ribavirin monophosphate.